Roche, Pfiz­er and Gilead lead rep­u­ta­tion rank­ings by pa­tient groups in an­nu­al sur­vey

Pa­tient groups con­tin­ue to hold a most­ly pos­i­tive opin­ion of the phar­ma in­dus­try, with the ma­jor­i­ty of re­spon­dents to a re­cent sur­vey giv­ing it an “ex­cel­lent” or “good” rat­ing.

While the score (60%) came in one per­cent­age point above Pa­tientView’s glob­al study av­er­age last year, it con­tin­ues an up­swing in pos­i­tive in­dus­try sen­ti­ment — from lows of 50% in 2020 and 46% in 2019. Among US pa­tient groups, the phar­ma sec­tor scored even high­er than av­er­age, with 65% of re­spon­dents re­port­ing pos­i­tive sen­ti­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER